ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Volume : 25 Issue : 6 Year : 2021
Quick Search



Twelve-month clinical outcomes of sirolimus-eluting stent in coronary artery disease: An experience in real-world Indian patients [Anatol J Cardiol]
Anatol J Cardiol. 2020; 24(6): 364-369 | DOI: 10.14744/AnatolJCardiol.2020.98452

Twelve-month clinical outcomes of sirolimus-eluting stent in coronary artery disease: An experience in real-world Indian patients

Srikanth Nathani1, Asif Raheem2, Harish Sanadhya3, Prakash Chandra Purohit3, Ramesh Patel3, Praveen K Alane4, Deepeshkumar Agarwal5, Ramanand Sinha5
1Department of Cardiology, Guntur Medical College; Andhra Pradesh-India
2Department of Cardiology, Divine Heart&Research Hospital; Gujarat-India
3Department of Cardiology, Geetanjali Medical College&Hospitals; Rajasthan-India
4Department of Cardiology, Mamata General Hospital; Telangana-India
5Department of Cardiology, Mahatma Gandhi Medical College&Hospital; Rajasthan-India

Objective: Supraflex (Sahajanand Medical Technologies Pvt. Ltd, Surat, India) is the latest generation of biodegradable polymer-coated sirolimus-eluting coronary stent designed on ultra-thin (60 µm) cobalt–chromium platform with flexible “S-link.” The present study was designed to establish the safety and clinical performance of Supraflex in real-world Indian patients with coronary artery disease.
Methods: The study included 839 consecutive patients with coronary artery disease who were implanted with Supraflex from January 2014 to August 2017 at six different tertiary care centers in India. Follow-up was performed at 30 days, 6 months, and 12 months after the index procedure. The primary end-point of the study was the incidence of major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction (MI), and target lesion revascularization (TLR) at the 12-month follow-up. The occurrence of stent thrombosis was analyzed as safety end-point.
Results: A total of 1025 lesions were treated by implantation of 1098 Supraflex stents. At the 12-month follow-up, MACE was 4.92%, including 7 (0.86%) cardiac deaths, 16 (1.97%) MI, and 17 (2.09%) TLR. Only three incidences of stent thrombosis were found at the 12-month follow-up.
Conclusion: The study results showed excellent safety and clinical effectiveness of Supraflex in a high proportion of high-risk real-world Indian patients with coronary artery disease.

Keywords: coronary artery disease, drug-eluting stents, percutaneous coronary intervention, sirolimus, stent thrombosis

Srikanth Nathani, Asif Raheem, Harish Sanadhya, Prakash Chandra Purohit, Ramesh Patel, Praveen K Alane, Deepeshkumar Agarwal, Ramanand Sinha. Twelve-month clinical outcomes of sirolimus-eluting stent in coronary artery disease: An experience in real-world Indian patients. Anatol J Cardiol. 2020; 24(6): 364-369

Corresponding Author: Srikanth Nathani, India